Last reviewed · How we verify
dofequidar fumarate — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
dofequidar fumarate (dofequidar fumarate) — European Organisation for Research and Treatment of Cancer - EORTC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| dofequidar fumarate TARGET | dofequidar fumarate | European Organisation for Research and Treatment of Cancer - EORTC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- dofequidar fumarate CI watch — RSS
- dofequidar fumarate CI watch — Atom
- dofequidar fumarate CI watch — JSON
- dofequidar fumarate alone — RSS
Cite this brief
Drug Landscape (2026). dofequidar fumarate — Competitive Intelligence Brief. https://druglandscape.com/ci/dofequidar-fumarate. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab